Expression feature and prognostic function of a novel immune checkpoint Siglec-15 in human colorectal cancer.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-07-30 DOI:10.14670/HH-18-801

Guodong Liang, Linyun Zhou, Yang Fan, Run Ding, Junrong Yang, Li Xu, Yidan Zhu, Wen Huang

{"title":"Expression feature and prognostic function of a novel immune checkpoint Siglec-15 in human colorectal cancer.","authors":"Guodong Liang, Linyun Zhou, Yang Fan, Run Ding, Junrong Yang, Li Xu, Yidan Zhu, Wen Huang","doi":"10.14670/HH-18-801","DOIUrl":null,"url":null,"abstract":"Background: Sialic acid-bound immunoglobulin lectin 15 (Siglec-15) plays an important role in the development of cancer. However, the association between Siglec-15 expression and clinicopathological characteristics of colorectal cancer (CRC) has not been fully investigated.Methods: In this present study, a number of bioinformatics analyses were performed to provide an overview and detailed characteristics of Siglec-15. Quantitative real-time polymerase chain reaction (qPCR), western blotting and immunohistochemistry analyses were conducted to characterize the expression of Siglec-15 in CRC. Kaplan-Meier survival and Cox regression analyses were performed to identify the prognostic parameters of CRC.Results: The results of bioinformatics analyses revealed the expression characteristics and prognostic roles of Siglec-15 in CRC. The data of qCPR, western blotting, and IHC analyses demonstrated that the expression of Siglec-15 in CRC tissues was significantly higher than that in non-cancerous tissues. Moreover, the expression level of Siglec-15 in CRC was significantly associated with lymph node metastasis (p=0.001), TNM stage (p=0.001), and overall survival (p=0.026). COX multi-factor analysis indicated that Siglec-15 expression (p=0.023) and tumor differentiation (p=0.003) were independent prognostic factors for CRC.Conclusions: Collectively, the data suggested that Siglec-15 expression may serve as a novel prognostic factor and Siglec-15 might be identified as an ideal candidate for immunotherapy in CRC treatment.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.14670/HH-18-801","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Sialic acid-bound immunoglobulin lectin 15 (Siglec-15) plays an important role in the development of cancer. However, the association between Siglec-15 expression and clinicopathological characteristics of colorectal cancer (CRC) has not been fully investigated.

Methods: In this present study, a number of bioinformatics analyses were performed to provide an overview and detailed characteristics of Siglec-15. Quantitative real-time polymerase chain reaction (qPCR), western blotting and immunohistochemistry analyses were conducted to characterize the expression of Siglec-15 in CRC. Kaplan-Meier survival and Cox regression analyses were performed to identify the prognostic parameters of CRC.

Results: The results of bioinformatics analyses revealed the expression characteristics and prognostic roles of Siglec-15 in CRC. The data of qCPR, western blotting, and IHC analyses demonstrated that the expression of Siglec-15 in CRC tissues was significantly higher than that in non-cancerous tissues. Moreover, the expression level of Siglec-15 in CRC was significantly associated with lymph node metastasis (p=0.001), TNM stage (p=0.001), and overall survival (p=0.026). COX multi-factor analysis indicated that Siglec-15 expression (p=0.023) and tumor differentiation (p=0.003) were independent prognostic factors for CRC.

Conclusions: Collectively, the data suggested that Siglec-15 expression may serve as a novel prognostic factor and Siglec-15 might be identified as an ideal candidate for immunotherapy in CRC treatment.

查看原文本刊更多论文

新型免疫检查点 Siglec-15 在人类结直肠癌中的表达特征和预后功能。

背景：Sialic酸结合免疫球蛋白凝集素15（Siglec-15）在癌症的发展中起着重要作用。然而，Siglec-15 的表达与结直肠癌（CRC）临床病理特征之间的关联尚未得到充分研究：本研究进行了一系列生物信息学分析，以提供 Siglec-15 的概况和详细特征。本研究对 Siglec-15 的表达进行了一系列生物信息学分析，以提供 Siglec-15 的概况和详细特征，并进行了实时定量聚合酶链反应（qPCR）、免疫印迹和免疫组化分析，以确定 Siglec-15 在 CRC 中的表达特征。通过卡普兰-梅耶生存分析和考克斯回归分析确定 CRC 的预后参数：结果：生物信息学分析结果显示了 Siglec-15 在 CRC 中的表达特点和预后作用。qCPR、Western印迹和IHC分析数据表明，Siglec-15在CRC组织中的表达明显高于非癌组织。此外，Siglec-15在CRC中的表达水平与淋巴结转移（p=0.001）、TNM分期（p=0.001）和总生存率（p=0.026）有明显相关性。COX多因素分析表明，Siglec-15的表达（p=0.023）和肿瘤分化（p=0.003）是CRC的独立预后因素：总之，这些数据表明，Siglec-15的表达可作为一种新的预后因素，Siglec-15可能被确定为CRC治疗中免疫疗法的理想候选者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464